Skip to main content
Revvity logo
Contact us
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States

Powering scientific intelligence.

Revvity unlocks the full potential of AI with trusted biological intelligence.

Revvity brings together AI-powered informatics, automation, reagents, imaging, analytical technologies, and scientific expertise to power connected Lab-in-the-Loop workflows that transform biological data into actionable scientific insight.

Learn more

Bridging the gap...

from research and discovery...

from research and discovery...

img-discovery-icon.png

Discovery

img-discovery.png
img-discovery-icon.png

Antibodies & tools for target & hit discovery

img-discovery-icon.png

Preclinical Development

img-clinical-development.jpg
img-preclinical-development-icon.png

Assays & platforms for lead & process development

img-clinical-development-icon.png

Clinical Development

img-market-approval.jpg
img-clinical-development-icon.png

Stratification and data management solutions

img-market-approval-icon.png

Market Approval

img-preclinical-development.jpg
img-discovery-icon.png

Solutions supporting product quality and efficacy

img-screening-icon.png

Screening

https://resources.revvity.com/images/img-screening.jpg
img-screening-icon.png

Screening tools for early detection

img-diagnostics-and-monitoring-icon.png

Diagnostics & Monitoring

img-diagnostics-and-monitoring.jpg
img-diagnostics-and-monitoring-icon.png

End-to-end solutions for specialty diagnostics

to diagnostics and cure.

img-omni-transition-nav-872x872.png

Explore Omni homogenizers

All your products and resources in one place.

Visit now
img-trymimix26-navigation-image.png

20% OFF your first Mimix order

Shop Mimix™ reference standards at HorizonDiscovery.com. T&Cs apply.

See details
img-render-opera-phenix-optIq-700x700.jpg

Opera Phenix OptIQ™ HCS system

Our new system for 3D models and live-cell applications.

Learn more

Industries we serve

img-academia-icon.svg
Academia
1.5K

new antibodies, kits, and reagents introduced annually for life science research.

27K

peer-reviewed publications using our In Vivo imaging systems.

5,650

published citations of Dharmacon™ reagents in 2023.

img-pharma-biotech-icon.svg
Pharma / Biotech
94%

of the top 50 pharmaceutical companies worldwide use our innovative solutions.

1,700

no-wash immunoassays and reagents for efficient screening.

2M+

scientists across pharma, biotech, and academia utilize our software solutions.

150

licensees across Revvity's technology and licensing organization.

img-clinical-laboratories-icon.svg
Clinical Laboratories
33M+

babies screened annually for life-threatening disorders with Revvity technologies.

85M+

blood samples analyzed with EUROIMMUN solutions to identify autoimmune disorders.

75M+

individuals tested for COVID-19 virus with Revvity tests.

20M+

individuals tested for latent TB infection with the T-SPOT.TB test since 2002.

img-healthcare-professionals-icon.svg
Healthcare Professionals
85

newborn lives saved daily.

550+

mentions of the T-SPOT.TB test in peer reviewed publications.

75+

years of innovation in maternal, fetal, and neonatal health.

300M+

genomic tests performed to detect rare inherited diseases and hereditary cancers.

img-cros-icon.svg
CROs
Top 10

CROs use our reagents, instruments and software to support their clients in commercializing their discoveries.

Top 25

CDMOs utilize our proven life science technologies to support their clients in every part of their commercialization journey.

safety-efficacy-512x288.jpg

Life Sciences

Revvity offers comprehensive life science solutions, technologies, and services, covering workflows from discovery to cure. We revolutionize biomedical research with a focus on translational multi-omics, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and more.

Cell and Gene Therapy
Biologics
Small Molecule Drug Discovery
Genomic Analysis
Protein Analysis
Cell Analysis
Instruments and Automation
View all

Popular reagent brands

BioLegend™
AlphaLISA™ and SureFire®
HTRF™
Dharmacon™

Popular instrument brands

Opera Phenix™
EnVision™
IVIS™
Fontus™
Cellometer™
Omni Bead Ruptor Elite™
LabChip™
Licensing and contract services

Licensing, Contract and Clinical Testing Services

Collaborate with our skilled scientists and experts to reach your goals sooner. Our range of contract services supports preclinical oncology drug discovery, viral vector manufacture, omics discovery, the development of genetic disease treatments, and clinical genetic testing. We also provide novel licensable technologies for gene expression, editing, and delivery to help you bring safer, more effective treatments to patients.

Preclinical Services
Viral Vector Engineering
Novel Technologies
Revvity Omics Services
Clinical Services
ViaCord®
View all

Contract services brands

OncoSignature™
CNGnome™
StepOne™

Licensing brands

CHOSOURCE™
LentiBOOST™
Pin-point™
Reproductive health

Reproductive Health

Our innovative laboratory solutions enhance reproductive health across all stages. Our cutting-edge research solutions drive innovation in reproductive health science, while our advanced screening technologies enable early detection and timely interventions, ultimately empowering improved outcomes globally.

Maternal and Prenatal Testing
Newborn Screening
Cell-free DNA Analysis
Pre-eclampsia Management
Pregnancy-related Infections
View all

Popular brands

Vanadis™
GSP™
EONIS™
EVOYA™
Immunodiagnostics

Immunodiagnostics

Our specialty portfolio delivers innovative, end-to-end solutions for identifying and investigating a broad range of immune system disorders. We integrate cutting-edge technologies, such as immunoassays, molecular assays, automation, and advanced software - to enable seamless workflow integration, ultimately expanding research and testing for these highly complex diseases.

Infectious Diseases
Allergy
Autoimmunity
Endocrinology
Neurodegeneration
Pathogen Detection
T-SPOT Technology
View all

Popular brands

T-SPOT™
EUROIMMUN
chemagic™
IDS

Featured Blogs

multiomics blog thumbnail
Integrating small RNA-seq and single-cell multiomics to investigate tumor-T-cell communication.

See how small RNA-seq and single-cell multiomics connect exosomal miRNA profiles with T-cell responses in triple-negative breast cancer research.

rana blog thumbnail
New meta-analysis of 307 studies finds that T-SPOT.TB is the most sensitive test for TB infection.

New meta-analysis of 307 studies confirms T-SPOT.TB as the most sensitive TB infection test — in both HIV-negative and HIV-positive populations.

in vivo editing blog thumbnail
High-efficiency in vivo editing with the Pin-point base editing system.

This blog discusses how the Pin-point™ base editing platform achieves high-efficiency in vivo editing following lipid nanoparticle delivery at modest RNA doses.

how to choose blog thumbnail
How to choose and analyze 3D culture.

Get a clear breakdown of how to choose between spheroids and organoids, and see how Revvity's Celigo image cytometer can help improve your 3D culture workflows.

achieving dual direction hero
Achieving dual-direction gene modulation with CRISPR activation and siRNA.

Explore how combining CRISPR activation and siRNA knockdown enables simultaneous bidirectional gene modulation to uncover drug resistance mechanisms and restore chemotherapeutic sensitivity.

cd34+ thumbnail
CD34+ cells: characterization and quality assessment with the Cellaca PLX cytometer.

Learn how to characterize CD34+ hematopoietic stem cell purity and viability using the Cellaca PLX automated cell counter. Explore Revvity’s research-grade HSC portfolio.

indeterminate blog thumbnail
A result you can act on: the evidence behind T-SPOT.TB's low indeterminate rates.

An indeterminate TB result means repeat draws and delays. Discover how the T-SPOT.TB test keeps indeterminate rates low

automated imaging and analysis blog thumbnail
Automated imaging and analysis of patient-derived organoids supports high-throughput evaluation of cancer drug response.

High-content imaging of patient-derived organoids can assist personalized cancer research using new approach methodologies.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Illuminator - About company

Our sustainable impact

img-2026-impact-report-cover.jpg

Advancing science and sustainability.

Explore more

News

Revvity to Present at Upcoming Investor Conferences
October 13, 2026
|
Press release
View more
Revvity to Host Investor Day
October 06, 2026
|
Press release
View more
Revvity to Hold Earnings Call on November 3, 2026
October 02, 2026
|
Press release
View more
View all

Careers

img-careers.png

Find your future at Revvity

Join Revvity's team of approximately 11,000 global colleagues and help us push boundaries in pursuit of better human health.

Careers

Investors

img-investors.jpg

Stay informed on the company's financial performance.

Investors
line

How can we help you?

We are here to answer your questions.

Contact us
Contact us
Request product information, quote/price request
Request product information
Order, shipping, invoice or service contact inquiry
Order, shipping, service contact inquiry
Instrument service request
Instrument service request
Revvity Logo

©2026 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.

Scroll Icon